Saturday, August 1, 2015

GlaxoSmithKline consolidating research facilities in suburban Philly

Drugmaker GlaxoSmithKline said Tuesday that it will consolidate employees from several facilities in suburban Philadelphia, with about 1200 moving from two facilities in Upper Merion to Upper Providence during the next two to four years.

GlaxoSmithKline consolidating research facilities in suburban Philly

0 comments

Drugmaker GlaxoSmithKline said Tuesday that it will consolidate employees from several facilities in suburban Philadelphia, with about 1900 moving from two facilities in Upper Merion to Upper Providence during the next two to four years.

Glaxo spokeswoman Melinda Stubbee said there are no planned layoffs in this portion of the corporate consolidation. However, Glaxo will also move a unit from Cambridge, Mass., to Upper Providence but not all 60 employees in that unit will be offered jobs in the new location.

The company has two facilities, what it calls Upper Merion East and Upper Merion West, on Swedeland Road. The East facility will remain in use and have some expansion. The West facility probably will be sold, Stubbee said, with employees moving to Upper Providence.

Glaxo rents space in the Renaissance Corporate Center is on Renaissance Boulevard in Upper Merion. The ease there will not be renewed and those employees would move to Upper Providence.

Glaxo, which is based in London, also is finishing a move of about 1300 employees from offices at Franklin Plaza in Center City to a new building in the Navy Yard. The company signed a 15-year lease for the Navy Yard facility.

 

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter